$VKTX (VIKING THERAPEUTICS) — 8-K: Viking's VK2735 Shows 22% Placebo-Adjusted Weight Loss at Week 33 With No Plateau

In a maintenance study, weekly subcutaneous VK2735 at 17.5 mg produced 22% placebo-adjusted weight loss at Week 33, with no plateau observed. Up to 97% of weight loss was maintained after transitioning to every-other-week dosing for three months, and up to 90% was maintained with monthly dosing. GI adverse event rates during maintenance were similar to placebo. The company plans an oral maintenance dosing part 2 study.

In a maintenance study, weekly subcutaneous VK2735 at 17.5 mg produced 22% placebo-adjusted weight loss at Week 33, with no plateau observed. Up to 97% of weight loss was maintained after transitionin